Moleculin Biotech Future Growth
Future criteria checks 0/6
Moleculin Biotech is forecast to grow earnings and revenue by 37.4% and 82.3% per annum respectively while EPS is expected to grow by 47.5% per annum.
Key information
37.4%
Earnings growth rate
47.5%
EPS growth rate
Biotechs earnings growth | 27.3% |
Revenue growth rate | 82.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 14 Aug 2024 |
Recent future growth updates
Recent updates
We're A Little Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 20Can Moleculin Biotech (NASDAQ:MBRX) Afford To Invest In Growth?
Jul 14Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Deliver On Growth Plans?
Feb 18Here's Why We're Watching Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Nov 01Moleculin Biotech rises 7% as WP1096 compound selected for NIAID-funded animal studies
Sep 27Moleculin brain cancer therapy WP1122 gets FDA orphan drug status
Sep 06Here's Why We're Not Too Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jul 11Moleculin potential COVID drug WP1122 shows safety in preliminary data from phase 1a trial
Jul 08We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Mar 28We're Not Very Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Rate
Dec 11We Think Moleculin Biotech (NASDAQ:MBRX) Can Afford To Drive Business Growth
Aug 18Moleculin Biotech to join Russell 2000 Index
Jun 15Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?
May 04Moleculin shares soar after promising Annamycin pre-clinical readout
Feb 02Moleculin Biotech under pressure on reverse stock split
Jan 29Here's Why We're A Bit Worried About Moleculin Biotech's (NASDAQ:MBRX) Cash Burn Situation
Jan 15Moleculin Bio's Annamycin an Orphan Drug in U.S. for soft tissue sarcomas
Dec 29Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -31 | N/A | N/A | 2 |
12/31/2025 | N/A | -29 | N/A | N/A | 2 |
12/31/2024 | N/A | -22 | N/A | N/A | 2 |
6/30/2024 | N/A | -25 | -26 | -26 | N/A |
3/31/2024 | N/A | -27 | -25 | -25 | N/A |
12/31/2023 | N/A | -30 | -24 | -24 | N/A |
9/30/2023 | N/A | -26 | -26 | -26 | N/A |
6/30/2023 | N/A | -29 | -26 | -26 | N/A |
3/31/2023 | N/A | -30 | -29 | -29 | N/A |
12/31/2022 | N/A | -29 | -28 | -28 | N/A |
9/30/2022 | N/A | -25 | -25 | -25 | N/A |
6/30/2022 | N/A | -21 | -21 | -21 | N/A |
3/31/2022 | N/A | -18 | -20 | -20 | N/A |
12/31/2021 | N/A | -16 | -19 | -19 | N/A |
9/30/2021 | N/A | -16 | -18 | -18 | N/A |
6/30/2021 | N/A | -15 | -19 | -19 | N/A |
3/31/2021 | N/A | -21 | -17 | -17 | N/A |
12/31/2020 | N/A | -17 | -18 | -18 | N/A |
9/30/2020 | N/A | -19 | -20 | -19 | N/A |
6/30/2020 | N/A | -19 | -17 | -17 | N/A |
3/31/2020 | N/A | -10 | -18 | -18 | N/A |
12/31/2019 | N/A | -13 | -17 | -17 | N/A |
9/30/2019 | N/A | -12 | -16 | -16 | N/A |
6/30/2019 | N/A | -10 | -16 | -15 | N/A |
3/31/2019 | N/A | -14 | -14 | -13 | N/A |
12/31/2018 | N/A | -12 | -13 | -12 | N/A |
9/30/2018 | N/A | -12 | -12 | -11 | N/A |
6/30/2018 | N/A | -13 | -10 | -10 | N/A |
3/31/2018 | N/A | -11 | N/A | -9 | N/A |
12/31/2017 | N/A | -10 | N/A | -7 | N/A |
9/30/2017 | N/A | -8 | N/A | -6 | N/A |
6/30/2017 | N/A | -7 | N/A | -5 | N/A |
3/31/2017 | N/A | -4 | N/A | -5 | N/A |
12/31/2016 | N/A | -4 | N/A | -4 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MBRX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MBRX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MBRX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MBRX is forecast to have no revenue next year.
High Growth Revenue: MBRX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MBRX's Return on Equity is forecast to be high in 3 years time